Chemed Corp. (NYSE:CHE) CFO David Patrick Williams sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 24th. The shares were sold at an average price of $301.11, for a total value of $3,011,100.00. Following the sale, the chief financial officer now owns 75,052 shares in the company, valued at $22,598,907.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

CHE opened at $310.10 on Friday. The company has a market cap of $4,950.84, a PE ratio of 57.85, a price-to-earnings-growth ratio of 2.80 and a beta of 1.06. Chemed Corp. has a one year low of $186.09 and a one year high of $313.25. The company has a current ratio of 0.91, a quick ratio of 0.88 and a debt-to-equity ratio of 0.26.

Chemed (NYSE:CHE) last released its earnings results on Thursday, April 19th. The company reported $2.72 EPS for the quarter, beating analysts’ consensus estimates of $2.36 by $0.36. The firm had revenue of $439.18 million for the quarter, compared to analysts’ expectations of $419.33 million. Chemed had a return on equity of 33.05% and a net margin of 6.67%. The company’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.82 earnings per share. equities research analysts predict that Chemed Corp. will post 10.96 earnings per share for the current year.

Chemed declared that its board has approved a share repurchase plan on Tuesday, March 6th that allows the company to buyback $150.00 million in outstanding shares. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its stock is undervalued.

A number of equities research analysts have issued reports on the company. Oppenheimer upped their price objective on Chemed from $270.00 to $275.00 and gave the company an “outperform” rating in a research report on Friday, February 16th. ValuEngine upgraded Chemed from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $339.00 price objective on the stock in a research report on Tuesday. Finally, Royal Bank of Canada restated a “hold” rating and set a $258.00 price objective on shares of Chemed in a research report on Friday, February 16th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $290.67.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CHE. Hengehold Capital Management LLC bought a new position in shares of Chemed during the fourth quarter valued at approximately $203,000. Tocqueville Asset Management L.P. bought a new position in shares of Chemed during the fourth quarter valued at approximately $205,000. D.A. Davidson & CO. bought a new position in shares of Chemed during the fourth quarter valued at approximately $209,000. Ellington Management Group LLC bought a new position in shares of Chemed during the fourth quarter valued at approximately $219,000. Finally, LS Investment Advisors LLC grew its stake in shares of Chemed by 60.7% during the fourth quarter. LS Investment Advisors LLC now owns 937 shares of the company’s stock valued at $228,000 after buying an additional 354 shares during the last quarter. 94.77% of the stock is currently owned by hedge funds and other institutional investors.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Insider Buying and Selling by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.